64 Section I • Head and Neck and Endocrine Procedures
◆ If the tumor location precludes identifi cation of the main trunk of the facial nerve using
standard techniques, the main trunk can be identifi ed using retrograde dissection along the
temporal, buccal, or marginal mandibular branch (most common) or via mastoidectomy.
◆ Parotid specimen and/or lymph nodes are sent for intraoperative frozen section analysis if
malignancy is suspected.
◆ The posterior auricular artery or its branch can cross the main trunk of the facial nerve and
cause signifi cant bleeding and inadvertent injury to the nerve if not properly identifi ed and
ligated.
◆ Facial paralysis or paresis can result from aggressive dissection or inadvertent injury of the
nerve. Recovery of facial nerve paresis/paralysis can occur over 3 to 4 weeks if neuropraxic
injury and up to 1 year if axon death has occurred.
◆ Hematoma formation, manifested by acute postoperative pain, swelling of fl ap, and oozing
from wound, demands reexploration and evacuation. Hematoma can cause airway compres-
sion if signifi cant. Extreme care must be taken to avoid injury to the exposed facial nerve.
◆ Skin fl ap necrosis is rare but can occur in heavy smokers and in the postauricular area
when the skin fl ap is too thin and the skin incision is made at an acute angle.
◆ Frey’s syndrome (gustatory sweating) is associated with sweating in the area of skin overlying
the parotid bed. Most patients have this to some degree, and it is typically subclinical. It
occurs because of the aberrant regrowth of parasympathetic motor fi bers from the auriculo-
temporal nerve into the sympathetic nerve fi bers controlling sweat glands. Raising thicker
subcutaneous fl aps may reduce its occurrence. Medical therapy includes topical
scopolamine. Surgical remedies are rarely successful (dermal graft, tympanic neurectomy).
◆ Postoperative sialocele or salivary fi stula (salivary drainage from wound) is rare and can
usually be successfully managed with aspiration and compression dressings. Atropine-like
drugs may be benefi cial.
SELECTED REFERENCES
1. Johnson JT: Parotid. In Myers EN, Carrau RL (eds): Operative Otolaryngology: Head and Neck Surgery,
1st ed. Philadelphia, Saunders, 1997, pp 504-518.
2. Olsen KD: Parotid superfi cial lobectomy. In Bailey BJ, Calhoun KH, Coffey AR, Neely JG: Atlas of Head &
Neck Surgery—Otolaryngology. Baltimore, Lippincott-Raven, 1996, pp 2-11.
3. Lore JM, Medina J: The parotid salivary gland and management of malignant salivary gland neoplasia. In
Lore JM, Medina J (eds): An Atlas of Head and Neck Surgery, 4th ed. Philadelphia, Saunders, 2005,
pp 861-891.
4. Olsen KD: Superfi cial parotidectomy. Oper Tech Gen Surg 2004;6:102-114.
5. Shah JP, Patel SG: Salivary glands. In Shah JP, Patel SG (eds): Head and Neck Surgery and Oncology,
3rd ed. Edinburgh, Mosby, 2003, pp 439-474.